LONDON (Alliance News) - Healthcare technology company Consort Medical PLC said it was trading well and in line with expectations Wednesday, and highlighted the launch of its new autoinjector product.
Its Bespak business' INJ300 autoinjector, which received regulatory approval from the US Food and Drug administration in February, was been launched with Dr. Reddy's Laboratories Ltd at the end of February.
"The launch of our first autoinjector represents a major milestone for Consort Medical's Injectables technology, confirms Bespak's capability in the autoinjector market, and is a significant step in the execution of our diversification strategy," said Chief Executive Jonathan Glenn in a statement Wednesday.
Consort noted that its financial position remained strong, with a net cash at February 28 of GBP30.5 million.
Shares in Consort are untraded. They last traded flat at 989.00 pence.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
